Colorectal Cancer Screening and Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Biomarker Test is the fastest growing sector, North America is the largest market

The Global Colorectal Cancer Screening and Diagnostic Market is projected to experience substantial growth, increasing from USD 18.78 billion in 2025 to USD 24.85 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 4.78%. This expansive market encompasses various medical devices, advanced stool-based assays, and sophisticated imaging systems specifically designed for the early detection of precancerous lesions and malignant growths within the colon and rectum.

Key factors propelling this market expansion include the rising global incidence of colorectal cancer and an increasingly aging population that requires more frequent health monitoring. Additionally, the implementation of national screening programs and revised guidelines that recommend lowering the screening age are actively broadening the eligible patient demographic. For instance, the American Cancer Society estimated 154,270 new colorectal cancer diagnoses in the United States alone in 2025, underscoring the critical need for effective diagnostic interventions.

Despite this promising growth trajectory, significant challenges impede the market's full potential, primarily stemming from low patient adherence to recommended screening protocols. The inherent invasiveness of conventional procedures, such as colonoscopies, coupled with the associated discomfort and extensive preparation requirements, frequently discourages eligible individuals from undergoing vital testing. This widespread aversion to invasive methods, alongside insufficient healthcare reimbursement structures prevalent in numerous developing regions, poses a substantial barrier to the widespread adoption of screening technologies, thus hindering overall market progression.

Market Drivers

A primary catalyst driving the market is the escalating global prevalence of colorectal cancer, particularly as diagnostic protocols are expanded to address the rising rates observed in younger demographics. Healthcare systems globally are intensifying their diagnostic efforts in direct response to this increasing disease burden, thereby necessitating the broad deployment of both established and innovative screening tools. This surge in disease incidence is not confined to older populations but is increasingly evident in early-onset cases, creating a sustained demand for diagnostic consumables and advanced imaging infrastructure across international healthcare networks. The World Health Organization reported in February 2024 that colorectal cancer had become the second leading cause of cancer death worldwide, with approximately 1.9 million new cases diagnosed in 2022, highlighting the urgent need for scalable diagnostic solutions.

Concurrently, the widespread adoption of non-invasive screening modalities is fundamentally transforming the diagnostic landscape by effectively overcoming historical barriers to patient compliance. The market is experiencing a rapid transition from traditional invasive colonoscopies toward more convenient alternatives such as stool-based DNA tests and liquid biopsies, which significantly enhance patient participation rates.

This shift is clearly demonstrated by the commercial success of next-generation screening products that integrate seamlessly into routine medical care. For example, Guardant Health's 'Shield FDA Approval Press Release' in July 2024 highlighted a completion rate exceeding 90% for their blood-based test in real-world settings, addressing the pressing need for accessible testing options. Furthermore, the financial performance of established companies like Exact Sciences, which reported $545 million in screening revenue in their 'Third Quarter 2024 Earnings Report' in November 2024, underscores the robust adoption and vitality of non-invasive diagnostic solutions.

Market Challenges

Low patient compliance with screening mandates represents a significant obstacle to the expansion of the Global Colorectal Cancer Screening and Diagnostic Market. This resistance largely stems from the intrusive nature of standard diagnostic procedures, notably colonoscopies, which often demand rigorous preparatory steps and induce physical discomfort. Consequently, a substantial portion of the eligible population either avoids or postpones necessary testing, directly diminishing the volume of procedures that typically drive demand for imaging systems and diagnostic consumables.

This disparity between the target patient demographic and actual participation creates a critical bottleneck for market growth. Even with updated guidelines broadening the eligible population, reluctance to undergo invasive testing substantially restricts the addressable market size for manufacturers of devices and assays. Data from the National Colorectal Cancer Roundtable in 2025 indicated that over one in three adults aged 45 and older were not screened according to recommendations. This statistic emphatically illustrates that market trajectory is not solely determined by disease prevalence or technological availability, but is crucially constrained by the persistent difficulty in achieving widespread patient adherence to screening protocols.

Market Trends

The integration of Artificial Intelligence (AI) into endoscopy is fundamentally enhancing the diagnostic accuracy of conventional colonoscopies by effectively reducing human error during polyp detection. This emerging trend focuses on implementing Computer-Aided Detection (CADe) systems that analyze video feeds in real-time, highlighting potential lesions and thereby addressing the variability in endoscopist performance. In contrast to the shift towards less invasive tools, this development strengthens the clinical value of invasive procedures by ensuring greater efficacy in identifying adenomas. A systematic review cited by Medscape in November 2024, titled 'AI-Assisted Colonoscopy Increases Adenoma Detection Rate by 20%: Meta-Analysis', demonstrated that AI-assisted colonoscopy boosted the adenoma detection rate by 20%, validating the technology's crucial role in minimizing missed diagnoses and improving patient outcomes.

Simultaneously, advancements in Multi-Omics and Novel Biomarker Discovery are expanding the market by targeting the large unscreened population with highly sensitive, next-generation assays. This trend is driven by the identification of complex RNA and DNA signatures that offer superior accuracy compared to traditional fecal testing, thereby incentivizing manufacturers to develop proprietary solutions for early-stage detection. The commercial impetus for this innovation lies in the vast untapped potential of eligible individuals who currently do not comply with existing screening protocols. According to Mainz Biomed's 'Mainz Biomed Enters Agreement with Quest Diagnostics' press release in December 2024, the persistent screening gap among United States residents represents a market opportunity exceeding $4.0 billion, fueling significant investment in novel biomarker validation to capture this addressable segment.

Key Market Players

• Exact Sciences Corporation
• Abbott Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Siemens Healthineers AG
• Hologic, Inc.
• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company

Report Scope

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, by Screening:

• Stool-Based Test
• Colonoscopy and Sigmoidoscopy
• Others

Colorectal Cancer Screening and Diagnostic Market, by Diagnostics:

• Biomarker Test
• Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, by End User:

• Hospitals and Clinics
• Clinical Laboratories
• Others

Colorectal Cancer Screening and Diagnostic Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.